CROSSLEND
12.10.2021 11:26:13 CEST | Business Wire | Press release
Berlin-based FinTech CrossLend has issued a note to facilitate an investment into lease contracts for bicycles. The transaction is the result of a collaboration between Bikeleasing - the fastest growing e-bike leasing provider, MEAG as asset manager, ERGO as investor, and CrossLend as the structurer and operator of the digital register. Scope rated the note as investment grade and confirmed the ecological impact of the issued note is in accordance with the ICMA Green Bond Principles as part of a second party opinion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005499/en/
The transaction reflects several market trends. The goals of a climate-neutral society require substantial investments to replace goods such as cars or heating devices which, in their normal lifespan, would still have years of operation ahead of them. At the same time, cost-intensive innovative products are being offered as part of convenient pay-as-you-go models which contain a lending product and require refinancing. As a result, highly innovative originators such as Bikeleasing are entering into an origination model in competition with banks, or even closing gaps where traditional banking products are not covering the needs of customers. The kinetics in terms of origination frequency, and the level of fragmentation seen in the single tickets of such originations, require a digital and data-driven transactional link to traditional capital market investors. Accordingly, CrossLend structured and issued a note on its digital asset register which complied with the ICMA Green Bond Principles.
"The transformation of the economy and society towards climate-friendly technologies requires unparalleled investments in a relatively short period of time. The reality is that non-digital investment banking cannot keep up with the kinetics of innovative product providers such as Bikeleasing. We are extremely proud that our digital asset technology closes a gap between agile, transformative products and the capital markets, enabling established institutions like MEAG and ERGO to conveniently invest to support ecological change," says Oliver Schimek, Chief Executive Officer of CrossLend GmbH.
According to Thomas Bayerl, Head of Illiquid Assets Debt at MEAG: "As an asset manager, we work in an environment where digital transformation and sustainability criteria play an increasing role in the development of investable assets. CrossLend's digital asset platform and register were instrumental in making this asset accessible for our client ERGO today. This transaction can serve as a successful example for further implementation possibilities in a variety of industries."
Paul Sinizin, co-founder and CEO of Bikeleasing comments: "Bikeleasing has been growing extremely fast and we still see a large untapped market opportunity ahead. For our growth we require a flexible and scalable funding source. Working with a technology platform like CrossLend allows us to minimise our operational efforts on the capital markets activity through automation and industrialisation."
About CrossLend
CrossLend is a FinTech company that provides full spectrum technology for loan asset transactions. Its mission is to make the world's lending and investment ecosystem more efficient, transparent, and profitable. Supervised by BaFIN and CSSF, CrossLend is backed by an array of prestigious equity investors from Europe and the US, including Mouro Capital (formerly Santander InnoVentures), Lakestar, CME Ventures, Earlybird, ABN AMRO's Digital Impact Fund, and the Luxembourg Future Fund (EIF and SNCI).
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005499/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
